{"id":51914,"date":"2024-06-25T19:29:33","date_gmt":"2024-06-25T18:29:33","guid":{"rendered":"https:\/\/www.innovationnewsnetwork.com\/?p=51914"},"modified":"2024-10-15T19:48:42","modified_gmt":"2024-10-15T18:48:42","slug":"defence-therapeutics-arm-x-vaccine-inhibits-ovarian-cancer-growth-treated-animals","status":"publish","type":"post","link":"https:\/\/www.innovationnewsnetwork.com\/defence-therapeutics-arm-x-vaccine-inhibits-ovarian-cancer-growth-treated-animals\/51914\/","title":{"rendered":"Defence Therapeutics’ ARM-X vaccine completely inhibits ovarian cancer growth in treated animals"},"content":{"rendered":"

Defence Therapeutics Inc., a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce that its second-generation ARM-X anti-cancer vaccine is therapeutically effective against pre-established ovarian cancer (ID8 model) when combined with the anti-PD-1 immune-checkpoint inhibitor.<\/h2>\n

Using\u00a0Defence\u2019s Accum\u00ae platform<\/a>, Defence previously demonstrated that AccuTOX\u00ae treatment of MSCs results in the induction of antigen cross-presentation capacity (ARM-X cells), which can mount potent anti-tumoral responses in animal pre-clinical models. This was previously achieved using various cancer models including solid T-cell lymphoma, melanoma and pancreatic cancer.\u00a0Defence<\/a> just completed an additional study where animals with pre-established ovarian cancer responded to a combination therapy including ARM-X and anti-PD-1. The latter group prolonged animal survival beyond 80 days post-vaccination, leading to a complete response in almost all treated animals as shown in Figure 1.<\/p>\n